• 1
    Yusuf S, Teo KK, Pogue J, et al.Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med.2008;358:15471559.
  • 2
    Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med.2008;148:3048.
  • 3
    Oparil S, Yarows SA, Patel S, et al.Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet.2007;370:221229.
  • 4
    Chrysant SG. The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan. Drugs Today (Barc).2010;46:151162.
  • 5
    Parving HH, Persson F, Lewis JB, et al.Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med.2008;358:24332446.
  • 6
    Parving HH, Brenner BM, McMurray JJ, et al.Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant.2009;24:16631671.
  • 7
    European Medicines Agency starts review of aliskiren-containing medicines following termination of ALTITUDE study. European Medicines Agency. Accessed May 9, 2012.
  • 8
    Phillips CO, Kashani A, Ko DK, et al.Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med.2007;167:19301936.
  • 9
    Lakhdar R, Al-Mallah MH, Lanfear DE. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail.2008;14:181188.
  • 10
    Mann JF, Schmieder RE, McQueen M, et al.Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet.2008;372:547553.
  • 11
    Pickering TG, Hall JE, Appel LJ, et al.Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension.2005;45:142161.
  • 12
    Verdecchia P, Schillaci G, Guerrieri M, et al.Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation.1990;81:528536.
  • 13
    Giles TD, Alessi T, Purkayastha D, Zappe D. Comparative efficacy of aliskiren/valsartan vs valsartan in nocturnal dipper and nondipper hypertensive patients: a pooled analysis. J Clin Hypertens (Greenwich).2012;14:299306.
  • 14
    Messerli FH, Staessen JA, Zannad F. Of fads, fashion, surrogate endpoints and dual RAS blockade. Eur Heart J.2010;31:22052208.
  • 15
    Bakris GL, Sarafidis PA, Weir MR, et al.Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet.2010;375:11731181.
  • 16
    Haller H, Ito S, Izzo JL Jr, et al.Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med.2011;364:907917.
  • 17
    Imai E, Chan JC, Ito S, et al.Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia.2011;54:29782986.
  • 18
    Adrogué HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. N Engl J Med.2007;356:19661978.
  • 19
    Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol.2009;30:418424.
  • 20
    Pitt B, Bakris G, Ruilope LM, et al.Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation.2008;118:16431650.
  • 21
    Edwards NC, Steeds RP, Chue CD, et al.The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br J Clin Pharmacol.2012;73:447454.
  • 22
    Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?Arch Intern Med.2000;160:685693.